Gufic Biosciences Ltd (GUFICBIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 509079 | NSE: GUFICBIO | Pharmaceuticals & Drugs | Small Cap

Gufic Biosciences Share Price

355.95 -1.90 -0.53%
as on 05-Dec'25 15:26

Gufic Biosciences Ltd (GUFICBIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 509079 | NSE: GUFICBIO | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Gufic Biosciences

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Gufic Biosciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
66.08
Market Cap:
3,588.6 Cr.
52-wk low:
285
52-wk high:
497.8

Is Gufic Biosciences Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Gufic Biosciences: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gufic Biosciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 24.2%24.3%34.1%29.7%21%30.1%47.3%23.2%17.6%13.5%-
Value Creation
Index
0.70.71.41.10.51.22.40.70.30.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 202246306351379488779691807820870
Sales YoY Gr.-21.4%24.5%14.8%8%28.7%59.8%-11.4%16.8%1.6%-
Adj EPS 11.11.92.82.44.59.88.48.77.15.4
YoY Gr.-12.1%74.8%43.3%-15.1%89%120.4%-14.2%3.4%-18.2%-
BVPS (₹) 4.44.879.713.317.927.835.953.16062.7
Adj Net
Profit
7.68.615.121.722.943.295.381.887.471.554
Cash Flow from Ops. -4.3-4.1-4.85.247.187.3106-26.6-7.5123-
Debt/CF from Ops. -9.9-13.7-16.518.82.50.60.6-11.7-42.52.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 16.8%16.7%1.7%1.6%
Adj EPS 24.5%24.8%-10.2%-18.2%
BVPS33.7%35.1%29.3%12.9%
Share Price 20.3% 24.7% 18.3% -20.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
2524.23333.522.328.543.126.519.912.68.8
Op. Profit
Mgn %
109.412.713.113.817.21919.918.616.914.8
Net Profit
Mgn %
3.83.54.96.268.912.211.810.88.76.3
Debt to
Equity
1.31.51.51.30.90.30.20.90.60.50.2
Working Cap
Days
187190201239254201136187213203139
Cash Conv.
Cycle
4067867384473155918351

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Gufic Biosciences Ltd.

Standalone Consolidated
TTM EPS (₹) 5.4 5.7
TTM Sales (₹ Cr.) 870 874
BVPS (₹.) 62.7 62.9
Reserves (₹ Cr.) 619 621
P/BV 5.71 5.69
PE 66.08 63.05
From the Market
52 Week Low / High (₹) 285.00 / 497.75
All Time Low / High (₹) 0.17 / 501.10
Market Cap (₹ Cr.) 3,589
Equity (₹ Cr.) 10
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Gufic Biosciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Gufic Biosciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Gufic Biosciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales202246306351379488779691807820
Operating Expenses 183223267305327404631556659683
Manufacturing Costs2732414751579387107125
Material Costs91107129161156226368295339310
Employee Cost 3241454759668687110127
Other Costs 3342525060558486103121
Operating Profit 202339465284148135147136
Operating Profit Margin (%) 9.7%9.3%12.7%13.1%13.8%17.2%19.0%19.5%18.3%16.6%
Other Income 1134643324
Interest 669101414581725
Depreciation 4445141619221721
Exceptional Items 0020000000
Profit Before Tax 10143035305812710711694
Tax 35131371331273024
Profit After Tax 791622234496808670
PAT Margin (%) 3.6%3.7%5.4%6.3%6.0%9.1%12.3%11.5%10.7%8.5%
Adjusted EPS (₹)1.01.22.12.82.34.69.98.28.67.0
Dividend Payout Ratio (%)5%4%2%2%2%2%1%1%1%1%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 34375475129173269348533601
Share Capital 8888101010101010
Reserves 26304668120164259338523591
Minority Interest0000000000
Debt405477961135255302296285
Long Term Debt87811203548191154130
Short Term Debt3247698593167112142154
Trade Payables53447678117111141130166159
Others Liabilities 264028614883578098125
Total Liabilities 1521752353104074195218601,0931,170

Fixed Assets

Gross Block51263137115149180246246614
Accumulated Depreciation2948133249648787108
Net Fixed Assets 2222232483100115160159506
CWIP 0021031134117030722
Investments 0000000123
Inventories5063949412294116183200217
Trade Receivables565281103107125152205330315
Cash Equivalents 6678161327471328
Others Assets 17322871487472958179
Total Assets 1521752353104074195218601,0931,170

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -4-4-554787106-27-7123
PBT 11143035305812710711694
Adjustment 9101213253123303444
Changes in Working Capital -21-24-30-3428-11-135-1307
Tax Paid -3-5-16-10-10-9-33-28-27-23
Cash Flow From Investing Activity -1-5-9-13-43-7-95-191-102-72
Capex -1-4-8-13-40-12-87-188-108-71
Net Investments 0000000-1-1-1
Others 0-1-10-36-7-27-0
Cash Flow From Financing Activity 57148-4-79-623482-37
Net Proceeds from Shares 000000001000
Net Proceeds from Borrowing -4-11371212107-37-24
Interest Paid -5-6-8-10-14-13-5-8-13-21
Dividend Paid -0-0-0-0-0-0-1-1-1-1
Others 141522153-77-12136338
Net Cash Flow -0-11-002517-2714

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)23.9925.3136.0333.8922.1729.2243.3125.8419.5712.34
ROCE (%)24.2424.2634.129.6521.0130.0547.2923.2317.5613.51
Asset Turnover Ratio1.531.591.551.321.091.261.81.160.960.97
PAT to CFO Conversion(x)-0.57-0.44-0.310.232.041.981.1-0.34-0.081.76
Working Capital Days
Receivable Days7676769398815981104107
Inventory Days747990951017645687569
Payable Days205164170174227184125168160191

Gufic Biosciences Ltd Stock News

Gufic Biosciences Ltd FAQs

The current trading price of Gufic Biosciences on 05-Dec-2025 15:26 is ₹355.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Gufic Biosciences stood at ₹3,588.6.
The latest P/E ratio of Gufic Biosciences as of 04-Dec-2025 is 66.08.
The latest P/B ratio of Gufic Biosciences as of 04-Dec-2025 is 5.71.
The 52-week high of Gufic Biosciences is ₹497.8 and the 52-week low is ₹285.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹870.1 ( Cr.) .

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

  • Pharmaceutical
  • Herbal
  • API / Bulk Drugs
  • Personal care
  • International

History and milestone

Past Initiatives

  • First Indian to produce Doxycycline Inj.
  • First Indian company to make Liquid Oxytetracycline Inj.
  • Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
  • First Company to launch Boswellia Serrata tablets
  • Pioneer in developing Kid tablet in India
  • Hived off Mox and Zole to Ranbaxy

2007-2009

  • Initiated contract manufacturing
  • Commenced international exports

2010-2015

  • Received patents for Anidulafungin and Tigecycline lyophilized inj.
  • Launched Criticare division

2016

  • Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
  • Launched Ferticare and Criticare Life divisions

2017-2019

  • Received patents for Rifabutin and Micafunginlyophilized inj.
  • Exported Vancomycin lyophilized Inj. to Germany
  • Manufacturing capacity ramped up to 31 million vials per annum
  • Launched Ferticare Life division

2020

  • Manufacturing Remdesivir for Hetero
  • Increased capacity to 48 million vials per annum

2022

  • Incorporated wholly owned subsidiary company namely ‘Gufic UK’
  • Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×